Sign up Australia
Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers’ research partner secures grant

Ellex Medical Lasers’ research partner secures grant

Ellex Medical Lasers’ (ASX:ELX) research collaborator Professor Erica Fletcher from the University of Melbourne has been awarded a $355,000 Australian Research Council (ARC) Linkage grant.

The funds will be used to detail the precise effects its 2RT laser has on cells, cell populations and the body as a whole.

It will provide fundamental knowledge on the impact of 2RT™on cell biology of immune cells and cell signalling pathways in the retina.

The work will also give Ellex’s researchers a better understanding of the mechanism of action and potential uses of the 2RT laser currently in use in clinical trials for the treatment of early-stage age-related macular degeneration.

During FY2015, sales of commercial 2RT units increased to early adopters and research collaborators in Holland, Germany, Italy, France, New Zealand and Australia.

As of 15th June 2015, these commercial 2RT units had been used to perform approximately 1,500 procedures on 940 patients. These patients and treatments are in addition to the patients being treated in the LEAD trial.

The potential market for AMS across the U.S., UK, Germany, France, Spain, Italy and Japan will almost double in value to $10.1 billion by 2023 from $5.1 billion in 2013.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

November 30 2016

Related Articles

scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
cholesterol on a dial
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use